Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review.

By K. Gupta, Jeffrey D. Miller, Jim Z. Li, M. Russell, C. Charbonneau. Cancer Treatment Reviews, 2008

971 citations recorded by the source corpus.

Subfields: Economics and Econometrics, Molecular Biology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/d31ae5dfbfc1be064a04e367e7baeab16fc8560a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. L. Kiemeney
2. B. Ljungberg
3. S. Campbell
4. D. Jacqmin
5. J. E. Lee
6. S. Weikert
7. H. Choi

Citations in the corpus

• The epidemiology of renal cell carcinoma. (2011, background): “For patients with mRCC, the prognosis is extremely poor, which makes the occurrence of mRCC a serious problem for oncologic health care around the world [1].”
• Cabozantinib versus everolimus in advanced renal cell carcinoma (2015, neutral): “Not reported 4 (2) 12 (6) 15 (5) 22 (7)”